The breast cancer immunotherapy pipeline is showing rapid development. This report presents findings on more than 30 candidate therapies, including 22 therapeutic vaccines and 11 antibodies. Of the 22 vaccines in development, 7 (32%) are at clinical phases II – III.
Drugs used to treat breast cancer fall into three main groups: hormonal blockers, chemotherapeutic agents and targeted antibodies. While these provide important treatment options for patients, their limitations (drug resistance, poor efficacy and side effects) have focused efforts on developing safer and more effective targeted therapies. Currently, the greatest growth in this field is in the development of breast cancer immunotherapies; therapeutic vaccines and antibodies.
This report presents a comprehensive review of the breast cancer immunotherapy pipeline, covering new candidate vaccines and antibodies. Currently, there are more than 20 candidate breast cancer vaccines in the pipeline. These include selective candidates, developed to target breast cancer and others, that are being evaluated against a number of cancer types, including breast cancer. This report also covers current developments on 11 antibodies, some of which are new molecules developed to selectively target breast cancer and others, that are being evaluated for a number of cancers, including breast cancer.
The development of candidate vaccines is seeing significant innovation, as companies establish novel biological strategies to stimulate the immune system to target antigens associated with breast cancer. Of the 22 candidate vaccines in development, 7 (32%) are at clinical phases II – III. This report also includes a technical overview of each of the candidate therapeutic vaccines and antibodies discussed.
The candidates vaccines and antibodies identified in this report target 17 different cancer antigens or (antibody) drug targets and these developments are being taken forward by 30 different companies. Of these, 23 (77%) are small and medium-sized organisations or groups, and seven are major multinational pharmaceutical companies. Of these candidates, two, three, one, eight, seven, seven and six are Approved or at Phase III, Phase II/III, Phase II, Phase I/II, Phase I or at the preclinical stage, respectively.
This report provides a comprehensive review on the breast cancer immunotherapy pipeline and presents summary clinical findings (pre-clinical to Phase III) on the candidates presented, including a discussion of current biological strategies to develop new immunotherapies. These developments are creating new partnering opportunities in this field.
Report Contents
Due to the nature of this report, details (name of candidate vaccine or therapeutic antibody, together with their respective antigen or target) in this report contents page, have been omitted.
Executive Summary
Chapter 1 Background p.7
1. Breast Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Staging
1.4 Current Treatments
1.5 This Report
Chapter 2 Breast Cancer Immunotherapy Strategies p.12
2.1 Vaccines & Antibodies
Chapter 3 Approved p.25
3.1 Summary
3.2 Approved Antibodies
3.3 Antibody, Approved
3.4 Antibody, Approved
Chapter 4 Phase III p.30
4.1 Summary
4.2 Phase III Vaccines and Antibodies
4.3 Antibody, Phase III
4.4 Antibody, Phase III
4.5 Vaccine, Phase III
Chapter 5 Phase II/III p.36
5.1 Summary
5.2 Phase II/III Vaccine
5.3 Vaccine, Phase II/III
Chapter 6 Phase II p.39
6.1 Summary
6.2 Phase I Vaccines & Antibodies
6.3 Vaccine, Phase II
6.4 Antibody, Phase II
6.5 Vaccine, Phase II
6.6 Vaccine, Phase II
6.7 Vaccine, Phase II
6.8 Antibody, Phase II
6.9 Antibody, Phase II
6.10 Vaccine, Phase II
Chapter 7 Phase I/II p.51
7.1 Summary
7.2 Phase I/II Vaccines & Antibodies
7.3 Vaccine, Phase I/II
7.4 Vaccine, Phase I/II
7.5 Biological, Phase I/II
7.6 Antibody, Phase I/II
7.7 Vaccine, Phase I/II
7.8 Vaccine, Phase I/II
7.9 Vaccine, Phase I/II
Chapter 8 Phase I p.62
8.1 Summary
8.2 Phase I Vaccines
8.3 Vaccine, Phase I
8.4 Vaccine, Phase I
8.5 Vaccine, Phase I
8.6 Vaccine, Phase I
8.7 Vaccine, Phase I
8.8 Vaccine, Phase I
8.9 Vaccine, Phase I
Chapter 9 Preclinical p.71
9.1 Summary
9.2 Phase I Vaccines and Antibodies
9.3 Vaccine, Preclinical
9.4 Antibody, Preclinical
9.5 Antibody, Preclinical
9.6 Antibody, Preclinical
9.7 Vaccine, Preclinical
9.8 Vaccine, Preclinical
Chapter 10 Discussion p.80
8.1 Discussion
Tables
Table 3.1 Breast cancer vaccines and therapeutic antibodies (Approved) (company, name, type (antibody or vaccine), antigen/target).
Table 4.1 Breast cancer vaccines and therapeutic antibodies (Phase III) (company, name, type (antibody or vaccine), antigen/target).
Table 5.1 Breast cancer vaccines and therapeutic antibodies ( Phase II/III) (company, name, type (antibody or vaccine), antigen/target).
Table 6.1 Breast cancer vaccines and therapeutic antibodies in (Phase II) (company, name, type (antibody or vaccine), antigen/target).
Table 7.1 Breast cancer vaccines and therapeutic antibodies (Phase I/II) (company, name, type (antibody or vaccine), antigen/target).
Table 8.1 Breast cancer vaccines and therapeutic antibodies ( Phase I) (company, name, type (antibody or vaccine), antigen/target).
Table 9.1 Breast cancer vaccines and therapeutic antibodies (Preclinical) (company, name, type (antibody or vaccine), antigen/target).
Figures
Figure 10.1 Breast cancer vaccines and therapeutic antibodies at Preclinical/Research, Phase I, Phase II, Phase III and Approved
Other selected research from the 'Oncology' category:
Triple Analysis: Breast Cancer, Leukemia and Peptides
Triple Analysis: Colorectal Cancer, Lung Cancer and Peptides
Other selected research from the 'Vaccines' category:
What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline
Commercial Insight: Vaccines - Reaching Adulthood